Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [3] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [3] Executive Compensation - The Board of Directors granted CEO Jean-Paul Kress an option to purchase 83,296,638 shares of common stock as an inducement for his employment [1] - The stock option has a ten-year term with an exercise price of $0.89 per share, equal to the closing price on June 26, 2025 [2] - The option will vest over a four-year period, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months [2]